|
Gene: CYB5A |
Gene summary for CYB5A |
Gene summary. |
Gene information | Species | Human | Gene symbol | CYB5A | Gene ID | 1528 |
Gene name | cytochrome b5 type A | |
Gene Alias | CYB5 | |
Cytomap | 18q22.3 | |
Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | P00167 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1528 | CYB5A | RNA-P17T-P17T-2 | Human | Lung | IAC | 5.20e-11 | -8.17e-01 | 0.3371 |
1528 | CYB5A | RNA-P17T-P17T-4 | Human | Lung | IAC | 2.23e-12 | -1.08e+00 | 0.343 |
1528 | CYB5A | RNA-P17T-P17T-6 | Human | Lung | IAC | 6.18e-15 | -8.86e-01 | 0.3385 |
1528 | CYB5A | RNA-P17T-P17T-8 | Human | Lung | IAC | 8.13e-16 | -6.83e-01 | 0.3329 |
1528 | CYB5A | RNA-P23T2-P23T2-2 | Human | Lung | MIAC | 1.92e-02 | -7.17e-01 | -0.028 |
1528 | CYB5A | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 2.36e-11 | -4.48e-02 | -0.2116 |
1528 | CYB5A | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 3.42e-09 | -2.09e-01 | -0.1941 |
1528 | CYB5A | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 1.04e-15 | 4.58e-02 | -0.2107 |
1528 | CYB5A | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 3.56e-09 | 1.07e-01 | -0.2119 |
1528 | CYB5A | RNA-P3T-P3T-1 | Human | Lung | IAC | 1.70e-13 | -1.31e+00 | 0.1829 |
1528 | CYB5A | RNA-P3T-P3T-2 | Human | Lung | IAC | 3.70e-15 | -1.29e+00 | 0.1835 |
1528 | CYB5A | RNA-P3T-P3T-3 | Human | Lung | IAC | 3.81e-04 | -1.56e+00 | 0.1745 |
1528 | CYB5A | RNA-P3T-P3T-4 | Human | Lung | IAC | 5.75e-18 | -1.25e+00 | 0.1859 |
1528 | CYB5A | RNA-P6T1-P6T1-1 | Human | Lung | MIAC | 2.83e-03 | -7.59e-01 | -0.0238 |
1528 | CYB5A | RNA-P6T1-P6T1-2 | Human | Lung | MIAC | 4.22e-02 | -7.52e-01 | -0.0186 |
1528 | CYB5A | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 1.04e-39 | -1.05e+00 | -0.0166 |
1528 | CYB5A | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.65e-48 | -1.10e+00 | -0.0132 |
1528 | CYB5A | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 6.01e-45 | -1.07e+00 | -0.013 |
1528 | CYB5A | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 4.89e-41 | -9.37e-01 | -0.0121 |
1528 | CYB5A | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 1.22e-13 | -7.80e-01 | -0.0961 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00060918 | Breast | Precancer | generation of precursor metabolites and energy | 94/1080 | 490/18723 | 1.54e-25 | 1.64e-22 | 94 |
GO:00229008 | Breast | Precancer | electron transport chain | 42/1080 | 175/18723 | 1.37e-15 | 4.59e-13 | 42 |
GO:19026008 | Breast | Precancer | proton transmembrane transport | 39/1080 | 157/18723 | 4.18e-15 | 1.18e-12 | 39 |
GO:00100389 | Breast | Precancer | response to metal ion | 47/1080 | 373/18723 | 3.88e-07 | 1.79e-05 | 47 |
GO:00466868 | Breast | Precancer | response to cadmium ion | 14/1080 | 68/18723 | 2.74e-05 | 6.21e-04 | 14 |
GO:000609113 | Breast | IDC | generation of precursor metabolites and energy | 103/1434 | 490/18723 | 1.53e-21 | 1.74e-18 | 103 |
GO:002290013 | Breast | IDC | electron transport chain | 51/1434 | 175/18723 | 2.23e-17 | 8.43e-15 | 51 |
GO:190260012 | Breast | IDC | proton transmembrane transport | 40/1434 | 157/18723 | 7.34e-12 | 1.34e-09 | 40 |
GO:001003814 | Breast | IDC | response to metal ion | 65/1434 | 373/18723 | 2.95e-10 | 3.42e-08 | 65 |
GO:004668613 | Breast | IDC | response to cadmium ion | 19/1434 | 68/18723 | 4.97e-07 | 2.45e-05 | 19 |
GO:000609123 | Breast | DCIS | generation of precursor metabolites and energy | 103/1390 | 490/18723 | 1.46e-22 | 1.65e-19 | 103 |
GO:002290023 | Breast | DCIS | electron transport chain | 51/1390 | 175/18723 | 6.01e-18 | 2.62e-15 | 51 |
GO:190260022 | Breast | DCIS | proton transmembrane transport | 40/1390 | 157/18723 | 2.77e-12 | 5.80e-10 | 40 |
GO:001003824 | Breast | DCIS | response to metal ion | 65/1390 | 373/18723 | 8.03e-11 | 9.88e-09 | 65 |
GO:004668623 | Breast | DCIS | response to cadmium ion | 19/1390 | 68/18723 | 3.07e-07 | 1.46e-05 | 19 |
GO:0006091 | Colorectum | AD | generation of precursor metabolites and energy | 209/3918 | 490/18723 | 3.17e-28 | 6.61e-25 | 209 |
GO:0022900 | Colorectum | AD | electron transport chain | 89/3918 | 175/18723 | 1.42e-18 | 8.91e-16 | 89 |
GO:1902600 | Colorectum | AD | proton transmembrane transport | 66/3918 | 157/18723 | 1.59e-09 | 1.17e-07 | 66 |
GO:0046686 | Colorectum | AD | response to cadmium ion | 27/3918 | 68/18723 | 3.19e-04 | 3.80e-03 | 27 |
GO:0010038 | Colorectum | AD | response to metal ion | 106/3918 | 373/18723 | 3.22e-04 | 3.83e-03 | 106 |
Page: 1 2 3 4 5 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CYB5A | SNV | Missense_Mutation | novel | c.232N>C | p.Thr78Pro | p.T78P | P00167 | protein_coding | tolerated(0.05) | benign(0.23) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CYB5A | SNV | Missense_Mutation | c.127N>C | p.Glu43Gln | p.E43Q | P00167 | protein_coding | deleterious(0.03) | benign(0.366) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
CYB5A | SNV | Missense_Mutation | novel | c.245N>A | p.Gly82Glu | p.G82E | P00167 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CYB5A | SNV | Missense_Mutation | c.48N>T | p.Glu16Asp | p.E16D | P00167 | protein_coding | tolerated(0.06) | probably_damaging(0.998) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
CYB5A | SNV | Missense_Mutation | rs370149747 | c.196N>A | p.Val66Ile | p.V66I | P00167 | protein_coding | deleterious(0.04) | benign(0.036) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
CYB5A | SNV | Missense_Mutation | novel | c.191N>T | p.Glu64Val | p.E64V | P00167 | protein_coding | deleterious(0) | probably_damaging(0.963) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CYB5A | SNV | Missense_Mutation | rs770734233 | c.175G>A | p.Ala59Thr | p.A59T | P00167 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-E6-A2P8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
CYB5A | SNV | Missense_Mutation | novel | c.364N>C | p.Ala122Pro | p.A122P | P00167 | protein_coding | deleterious(0.01) | benign(0.328) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CYB5A | SNV | Missense_Mutation | novel | c.392N>C | p.Met131Thr | p.M131T | P00167 | protein_coding | tolerated(0.83) | benign(0) | TCGA-FI-A2F4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CYB5A | deletion | Frame_Shift_Del | novel | c.84_96delNNNNNNNNNNNNN | p.Ile29ArgfsTer5 | p.I29Rfs*5 | P00167 | protein_coding | TCGA-CC-A3MC-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |